Capital Impact Advisors LLC Sells 1,276 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Capital Impact Advisors LLC cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 42.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,754 shares of the company’s stock after selling 1,276 shares during the period. Medpace makes up approximately 2.0% of Capital Impact Advisors LLC’s investment portfolio, making the stock its 19th largest holding. Capital Impact Advisors LLC’s holdings in Medpace were worth $722,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. US Bancorp DE lifted its holdings in shares of Medpace by 1.9% during the 4th quarter. US Bancorp DE now owns 5,269 shares of the company’s stock valued at $1,615,000 after purchasing an additional 98 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in Medpace during the 4th quarter worth approximately $2,394,000. Steward Partners Investment Advisory LLC bought a new position in Medpace in the fourth quarter valued at approximately $255,000. Stifel Financial Corp boosted its holdings in shares of Medpace by 29.4% in the fourth quarter. Stifel Financial Corp now owns 31,379 shares of the company’s stock valued at $9,619,000 after buying an additional 7,125 shares during the period. Finally, Allianz Asset Management GmbH increased its position in shares of Medpace by 10.0% during the fourth quarter. Allianz Asset Management GmbH now owns 15,897 shares of the company’s stock worth $4,873,000 after acquiring an additional 1,440 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on MEDP shares. UBS Group cut shares of Medpace from a “buy” rating to a “neutral” rating and cut their price objective for the company from $420.00 to $350.00 in a research report on Friday. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and cut their price target for the company from $415.00 to $345.00 in a report on Wednesday, September 25th. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft reduced their price target on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research report on Wednesday, July 24th. Finally, Guggenheim cut their price objective on shares of Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research report on Wednesday, July 24th. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $395.00.

Medpace Stock Performance

MEDP opened at $331.44 on Monday. The stock has a market capitalization of $10.27 billion, a PE ratio of 33.79, a price-to-earnings-growth ratio of 1.88 and a beta of 1.35. The stock’s 50 day moving average price is $368.39 and its 200-day moving average price is $389.57. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, July 22nd. The company reported $2.75 EPS for the quarter, topping the consensus estimate of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The business had revenue of $528.10 million for the quarter, compared to the consensus estimate of $528.41 million. During the same period in the previous year, the company posted $1.93 earnings per share. The company’s revenue for the quarter was up 14.6% compared to the same quarter last year. Research analysts forecast that Medpace Holdings, Inc. will post 11.66 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.